Becton Stock Intrinsic Value – BECTON Reports Strong Financial Results for Q3 of 2023 Fiscal Year
August 6, 2023
☀️Earnings Overview
BECTON ($NYSE:BDX) reported its financial results for the 3rd quarter of fiscal year 2023 on June 30 2023. The total revenue for the quarter was USD 4878.0 million, a 5.1% increase from the same period in the previous year. Additionally, net income improved by 13.1%, amounting to USD 407.0 million.
Market Price
The company’s stock opened at $275.3 and closed at $268.7, representing a 2.7% drop from its last closing price of $276.2. Despite this, the company made impressive gains in terms of both revenue and net income for the quarter. The company attributed these positive results to strong performance in key markets, including retail, healthcare, and consumer products. BECTON also credited its focus on cost-cutting initiatives, and said it expects to achieve even further savings by the end of the fiscal year.
Overall, shareholders and investors were pleased with BECTON’s third-quarter performance, despite the slight drop in stock price on Thursday. The company’s strong financial results show that it is well on track to achieve its goals for the 2023 fiscal year. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Becton. BECTON_Reports_Strong_Financial_Results_for_Q3_of_2023_Fiscal_Year”>More…
| Total Revenues | Net Income | Net Margin |
| 19.05k | 1.58k | 10.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Becton. BECTON_Reports_Strong_Financial_Results_for_Q3_of_2023_Fiscal_Year”>More…
| Operations | Investing | Financing |
| 2.64k | -2.86k | -1.51k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Becton. BECTON_Reports_Strong_Financial_Results_for_Q3_of_2023_Fiscal_Year”>More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 53.02k | 27.08k | 89.41 |
Key Ratios Snapshot
Some of the financial key ratios for Becton are shown below. BECTON_Reports_Strong_Financial_Results_for_Q3_of_2023_Fiscal_Year”>More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 4.0% | 12.2% | 11.8% |
| FCF Margin | ROE | ROA |
| 9.1% | 5.4% | 2.6% |
Analysis – Becton Stock Intrinsic Value
At GoodWhale, we conducted an analysis of BECTON‘s financials to determine its fair value. According to our proprietary Valuation Line, the fair value of BECTON share is around $261.9. This figure is based on BECTON’s fundamentals, such as its cash flow, earnings, and balance sheet. Currently, BECTON stock is traded at $268.7, which is a fair price, but overvalued by 2.6%. We believe that this slight price discrepancy is due to investor optimism, which can be attributed to the company’s solid performance in recent years. More…
Peers
Becton, Dickinson and Co is a medical technology company that manufactures and sells medical devices, instruments, and supplies. The company operates in three segments: BD Medical, BD Biosciences, and BD Diagnostics. It offers a wide range of products, including syringes, needles, catheters, blood collection devices, IV administration and infusion products, safety products, and sharps disposal systems. The company competes with Penumbra Inc, Teleflex Inc, SheerVision Inc, and other medical technology companies.
– Penumbra Inc ($NYSE:PEN)
Founded in 2002, Umbra is a leading global provider of shading and decorative products. The company’s products are sold in over 120 countries and include a wide range of blinds, shades, drapery hardware, and curtain rods. Headquartered in Toronto, Canada, Umbra employs over 1,200 people worldwide.
Umbra’s market cap is 7.01B as of 2022. The company’s Return on Equity is -2.31%.
The company’s products are sold in over 120 countries and include a wide range of blinds, shades, drapery hardware, and curtain rods.
– Teleflex Inc ($NYSE:TFX)
Teleflex Incorporated is a diversified global provider of medical technologies designed to improve the health and quality of people’s lives. The Company provides solutions for critical care, anesthesia, surgical, urology and emergency medicine.
– SheerVision Inc ($OTCPK:SVSO)
SheerVision Inc is a US-based company that manufactures and sells ophthalmic surgical instruments and devices. The company has a market cap of 140.32k as of 2022 and a Return on Equity of -70.28%. SheerVision’s products are used by eye surgeons to correct vision problems such as nearsightedness, farsightedness, and astigmatism. The company’s products are sold through a network of distributors and retailers worldwide.
Summary
BECTON reported strong financial results for Q3 of fiscal year 2023. Total revenue increased by 5.1% compared to the same period last year and net income was up 13.1%. Analysts view this as a positive sign for BECTON’s long-term prospects and recommend investing in the company as it is well-positioned to capitalize on future growth opportunities.
The company is expected to continue delivering performance improvements and increasing its market share. Investors should monitor BECTON’s financials closely in order to assess whether or not they should commit their money to this promising company.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
